Efficacy and safety of lanreotide autogel compared with lanreotide [amount hidden] prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)

What Was Tested

Researchers studied Somatostatin and Lanreotide in this clinical trial, phase iii publication.

Lanreotide autogel is a somatostatin analog (SSA) approved for the treatment of acromegaly in 73 countries worldwide; however, it is not yet approved in China.

Retrospectively registered on ClinicalTrials.gov: NCT02493517 (9 July 2015); prospectively registered on chinadrugtrials.org.cn: CTR20140698 (24 October 2014).

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

The participants were allocated by chance, so the Somatostatin group and the comparison group should start out alike.

Nothing was hidden in this open-label Somatostatin study: the participants and staff both knew the treatment.

Primary endpoint was mean change-from-baseline in age-adjusted insulin-like growth factor-1 (IGF-1) standard deviation scores (SDS) at the end-of-study.

What Was Measured

PubMed files the paper under topics including Adenoma, Antineoplastic Agents, Blood Glucose, China, Glycated Hemoglobin, Growth Hormone-Secreting Pituitary Adenoma and Human Growth Hormone.

The authors tagged it with the keywords Acromegaly, Chinese patients, Clinical trial, Lanreotide, Lanreotide autogel and Somatostatin analogs.

What This Means in Plain Language

The paper is a randomized and open-label study of Somatostatin and Lanreotide.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (BMC endocrine disorders), a journal based in England.

More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.